More Capacity and Technology Translate to More Options
Technology and capacity investments create opportunities in the cell and gene therapy arena for CDMOs and biopharma alike.
Emerging therapies are testing the capabilities of biologic drug manufacturing companies, as well as contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). Manufacturers are employing process optimization and scalable advanced technologies to produce more product in less floor space. In addition, CDMOs have stepped up investments in cell and gene therapy development and manufacturing While this consolidation means there are fewer competitors in the market, industry experts see benefits including standardization of methods, simplified vendor management, and use of advanced technologies.
Read this article in BioPharm International’s February 2020 Partnerships for Outsourcing eBook.
Article Details
BioPharm International
eBook: Outsourcing Resources, February 2020
February 2020
Page: 6
Citation
When referring to this article, please cite it as R.Peters, “More Capacity and Technology Translate to More Options," BioPharm International Outsourcing ResourceseBook (February 2020).
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
